# Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305

> **NCT00689403** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 50 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD1305
- **DRUG:** AZD1305

## Key facts

- **NCT ID:** NCT00689403
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2010-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689403, "Evaluate Different Extended-release (ER) Tablets/Capsules of AZD1305". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00689403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*